Katarzyna MazurHofsaess - Fresenius Medical CEO
| FMS Stock | USD 21.48 0.93 4.53% |
CEO
Dr. Katarzyna MazurHofsaess was Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa of Fresenius Medical Care AG Co. KGaA since September 1, 2018. Before joining the Company, she had been President for EMEA at the medtech company Zimmer Biomet since 2013. She has 25 years of professional experience and held various positions in the medical and pharmaceutical industry from her positions, among others at Abbott Laboratories and Roche. since 2022.
| Age | 58 |
| Tenure | 2 years |
| Professional Marks | Ph.D |
| Address | Else-KrOener-Strasse 1, Bad Homburg, Germany, 61352 |
| Phone | 49 6172 609 0 |
| Web | https://www.freseniusmedicalcare.com |
Fresenius Medical Management Efficiency
The company has Return on Asset of 0.0273 % which means that on every $100 spent on assets, it made $0.0273 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0484 %, implying that it generated $0.0484 on every 100 dollars invested. Fresenius Medical's management efficiency ratios could be used to measure how well Fresenius Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.07 in 2024, whereas Return On Tangible Assets are likely to drop 0.03 in 2024. At this time, Fresenius Medical's Other Current Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 1.7 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.8 B in 2024.Similar Executives
| Found 4 records | CEO Age | ||
| Theodore CPA | Healthcare Services Group | 50 | |
| April Anthony | Encompass Health Corp | 53 | |
| Mark Tarr | Encompass Health Corp | 62 | |
| Debra Osteen | Acadia Healthcare | 62 | |
Management Performance
| Return On Equity | 0.0484 | ||||
| Return On Asset | 0.0273 |
Fresenius Medical Care Leadership Team
Elected by the shareholders, the Fresenius Medical's board of directors comprises two types of representatives: Fresenius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius Medical's management team and ensure that shareholders' interests are well served. Fresenius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver Maier, Senior Vice President of Investor Relations | ||
| Roberto Fuste, Member of the Management Board for Asia-Pacific | ||
| Walter Weisman, Member of the Supervisory Board | ||
| Michael Brosnan, CFO of Fresenius Medical Care Management AG and Member of the Management Board - Fresenius Medical Care Management AG | ||
| Pascale Witz, Independent Member of the Supervisory Board | ||
| GailSuzanne Brown, Senior Development | ||
| Katarzyna MazurHofsab, Management AG | ||
| Borries Muller, Senior Communications | ||
| FACHE MBA, CEO Board | ||
| Kent Wanzek, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Global Manufacturing and Quality - Fresenius Medical Care Management AG | ||
| Joachim Weith, Senior Affairs | ||
| Deborah McWhinney, Member of the Supervisory Board | ||
| Robert Powell, Chairman Board | ||
| Franklin FACP, Global AG | ||
| Gregory Sorensen, Independent Member of the Supervisory Board | ||
| Dorothea Wenzel, Independent Member of the Supervisory Board | ||
| Martin Fischer, CFO AG | ||
| Glenn Slater, Senior Operations | ||
| Dieter Schenk, Vice Chairman of the Supervisory Board | ||
| Katarzyna MazurHofsaess, Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa (EMEA) Segment | ||
| Ronald Kuerbitz, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Fresenius Medical Care North America - Fresenius Medical Care Management AG | ||
| Dominik Wehner, Member of the Management Board for Europe, Middle East and Africa | ||
| Gregor Zuend, Independent Member of the Supervisory Board | ||
| Rolf Classon, Independent Vice Chairman of the Supervisory Board | ||
| Helen Giza, Chief Financial Officer, Member of the Management Board, Chief Transformation Officer | ||
| Ben Lipps, Honorary Chairman | ||
| Gregor Zund, Member of the Supervisory Board | ||
| Bernd Fahrholz, Member of the Supervisory Board | ||
| Nwamaka MD, Head Operations | ||
| William Johnston, Independent Member of the Supervisory Board | ||
| Olaf Schermeier, CEO of Global RandD at Fresenius Medical Care Management AG and Member of the Management Board at Fresenius Medical Care Management AG | ||
| Dominik Heger, Head of Investor Relations & Corporate Communications | ||
| Frank Maddux, Member of the Management Board, Global Chief Medical Officer | ||
| William Valle, Member of the Management Board, Chief Executive Officer for the North America Segment | ||
| Rice Powell, Chairman of the Management Board, Chief Executive Officer | ||
| Harry Wit, Member of the Management Board, Chief Executive Officer for the Asia-Pacific Segment | ||
| Wolfgang Kummerle, Senior International | ||
| Carla Kriwet, CEO Care | ||
| Gerd Krick, Chairman of the Supervisory Board |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fresenius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0484 | ||||
| Return On Asset | 0.0273 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 18 B | ||||
| Shares Outstanding | 586.83 M | ||||
| Shares Owned By Institutions | 7.30 % | ||||
| Number Of Shares Shorted | 1.1 M | ||||
| Price To Earning | 6.53 X | ||||
| Price To Book | 0.74 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Fresenius Stock analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Fresenius Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fresenius Medical. If investors know Fresenius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fresenius Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.353 | Dividend Share 1.19 | Earnings Share 0.91 | Revenue Per Share 33.1505 | Quarterly Revenue Growth (0) |
The market value of Fresenius Medical Care is measured differently than its book value, which is the value of Fresenius that is recorded on the company's balance sheet. Investors also form their own opinion of Fresenius Medical's value that differs from its market value or its book value, called intrinsic value, which is Fresenius Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fresenius Medical's market value can be influenced by many factors that don't directly affect Fresenius Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fresenius Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fresenius Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fresenius Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.